<DOC>
	<DOCNO>NCT02265302</DOCNO>
	<brief_summary>Study obtain information safety tolerability BIIL 248 BS , find pharmacologically active dose range two formulation PSE 1 % WIF tablets determination surrogate marker CD11b ( = Mac-1 ) obtain preliminary pharmacokinetic data well first information food effect administration 75 mg WIF tablet healthy male volunteer</brief_summary>
	<brief_title>Safety , Tolerability , Biological Effects Pharmacokinetics BIIL 284 BS Healthy Males</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Healthy male subject determine result screen Age ≥ 21 ≤ 50 year Broca ≥ 20 % ≤ + 20 % Signed write informed consent accordance Good Clinical Practice local legislation Results medical examination laboratory test judge clinical investigator differ significantly normal clinical value Known gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Diseases central nervous system ( epilepsy ) psychiatric disorder Known history orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator Intake drug long halflife ( ≥ 24 hour ) within least one month less ten halflives respective drug enrolment study Intake drug might influence result trial week previous start study Participation another study investigational drug within last two month precede study Smokers ( &gt; 5 cigarette 2 cigar 2 pipes/day ) Volunteer able refrain smoking study day Alcohol abuse ( 60 g alcohol per day ) Drug abuse Excessive physical activity ( e.g . competitive sport ) within last week study Blood donation within last 4 week ( ≥ 100 ml )</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>